Skip to main content
Erschienen in: Current Psychiatry Reports 1/2010

01.02.2010

Sensitivity to Antipsychotic Drugs in Older Adults

verfasst von: Chloe Leon, Philip Gerretsen, Hiroyuki Uchida, Takefumi Suzuki, Tarek Rajji, David C. Mamo

Erschienen in: Current Psychiatry Reports | Ausgabe 1/2010

Einloggen, um Zugang zu erhalten

Abstract

Antipsychotic medications are widely used to manage psychotic and behavioral disorders in older adults, including primary psychotic disorders such as schizophrenia, and psychosis and behavioral disturbances associated with dementia. These two broad diagnostic indications are associated with contrasting recommended treatment durations, with the former requiring indefinite treatment across the life span. Antipsychotic drug dosing for schizophrenia is based primarily on studies of younger patients and thus may not apply to older adults. It is critically important to address the effects of aging on antipsychotic dosing given the recent emergence of data that suggest a critical role for age-related sensitivity to these drugs. Antipsychotic drugs are not only associated with somatic and neurological adverse effects but also increased all-cause mortality and sudden cardiac death in this vulnerable population. This review focuses on the sensitivity of older adults to adverse effects from antipsychotic medications and the current pharmacokinetic and pharmacodynamic explanatory models of susceptibility. Implications of recent research findings for individualized pharmacotherapy are discussed.
Literatur
1.
Zurück zum Zitat Jeste DV, Dolder CR, Nayak GV, Salzman C: Atypical antipsychotics in elderly patients with dementia or schizophrenia: review of recent literature. Harv Rev Psychiatry 2005, 13:340–351.CrossRefPubMed Jeste DV, Dolder CR, Nayak GV, Salzman C: Atypical antipsychotics in elderly patients with dementia or schizophrenia: review of recent literature. Harv Rev Psychiatry 2005, 13:340–351.CrossRefPubMed
2.
Zurück zum Zitat Wang PS, Schneeweiss S, Avorn J, et al.: Risk of death in elderly users of conventional vs. atypical antipsychotic medications. N Engl J Med 2005, 353:2335–2341.CrossRefPubMed Wang PS, Schneeweiss S, Avorn J, et al.: Risk of death in elderly users of conventional vs. atypical antipsychotic medications. N Engl J Med 2005, 353:2335–2341.CrossRefPubMed
3.
Zurück zum Zitat •• Ray WA, Chung CP, Murray KT, et al.: Atypical antipsychotic drugs and the risk of sudden cardiac death. N Engl J Med 2009, 360:225–235. (Published erratum appears in N Engl J Med 2009, 361:1814). This retrospective cohort study found that current users of typical and atypical antipsychotic drugs had a similar dose-related increased risk of sudden cardiac death.CrossRefPubMed •• Ray WA, Chung CP, Murray KT, et al.: Atypical antipsychotic drugs and the risk of sudden cardiac death. N Engl J Med 2009, 360:225–235. (Published erratum appears in N Engl J Med 2009, 361:1814). This retrospective cohort study found that current users of typical and atypical antipsychotic drugs had a similar dose-related increased risk of sudden cardiac death.CrossRefPubMed
4.
Zurück zum Zitat Jeste DV, Alexopoulos GS, Bartels SJ, et al.: Consensus statement on the upcoming crisis in geriatric mental health: research agenda for the next 2 decades. Arch Gen Psychiatry 1999, 56:848–853.CrossRefPubMed Jeste DV, Alexopoulos GS, Bartels SJ, et al.: Consensus statement on the upcoming crisis in geriatric mental health: research agenda for the next 2 decades. Arch Gen Psychiatry 1999, 56:848–853.CrossRefPubMed
5.
Zurück zum Zitat Colenda CC, Mickus MA, Marcus SC, et al.: Comparison of adult and geriatric psychiatric practice patterns: findings from the American Psychiatric Association’s Practice Research Network. Am J Geriatr Psychiatry 2002, 10:609–617.PubMed Colenda CC, Mickus MA, Marcus SC, et al.: Comparison of adult and geriatric psychiatric practice patterns: findings from the American Psychiatric Association’s Practice Research Network. Am J Geriatr Psychiatry 2002, 10:609–617.PubMed
6.
Zurück zum Zitat Rapoport M, Mamdani M, Shulman KI, et al.: Antipsychotic use in the elderly: shifting trends and increasing costs. Int J Geriatr Psychiatry 2005, 20:749–753.CrossRefPubMed Rapoport M, Mamdani M, Shulman KI, et al.: Antipsychotic use in the elderly: shifting trends and increasing costs. Int J Geriatr Psychiatry 2005, 20:749–753.CrossRefPubMed
7.
Zurück zum Zitat Alexopoulos GS, Streim J, Carpenter D, Docherty JP; Expert Consensus Panel for Using Antipsychotic Drugs in Older Patients: Using antipsychotic agents in older patients. J Clin Psychiatry 2004, 65(Suppl 2):5–99.PubMed Alexopoulos GS, Streim J, Carpenter D, Docherty JP; Expert Consensus Panel for Using Antipsychotic Drugs in Older Patients: Using antipsychotic agents in older patients. J Clin Psychiatry 2004, 65(Suppl 2):5–99.PubMed
8.
Zurück zum Zitat Katz IR, Jeste DV, Mintzer JE, et al.: Comparison of risperidone and placebo for psychosis and behavioral disturbances associated with dementia: a randomized, double-blind trial. Risperidone Study Group. J Clin Psychiatry 1999, 60:107–115.PubMed Katz IR, Jeste DV, Mintzer JE, et al.: Comparison of risperidone and placebo for psychosis and behavioral disturbances associated with dementia: a randomized, double-blind trial. Risperidone Study Group. J Clin Psychiatry 1999, 60:107–115.PubMed
9.
Zurück zum Zitat Alexopoulos GS, Jeste DV, Chung H, et al.: The expert consensus guideline series. Treatment of dementia and its behavioral disturbances. Introduction: methods, commentary, and summary. Postgrad Med 2005, Jan:6–22. Alexopoulos GS, Jeste DV, Chung H, et al.: The expert consensus guideline series. Treatment of dementia and its behavioral disturbances. Introduction: methods, commentary, and summary. Postgrad Med 2005, Jan:6–22.
10.
Zurück zum Zitat • Uchida H, Mamo DC, Mulsant BH, et al.: Increased antipsychotic sensitivity in elderly patients: evidence and mechanisms. J Clin Psychiatry 2009, 70:397–405. This is a review of the evidence for hypotheses thought to contribute to age-related antipsychotic sensitivity.CrossRefPubMed • Uchida H, Mamo DC, Mulsant BH, et al.: Increased antipsychotic sensitivity in elderly patients: evidence and mechanisms. J Clin Psychiatry 2009, 70:397–405. This is a review of the evidence for hypotheses thought to contribute to age-related antipsychotic sensitivity.CrossRefPubMed
11.
Zurück zum Zitat • Uchida H, Mamo DC: Dosing of antipsychotics in schizophrenia across the life-spectrum. Prog Neuropsychopharmacol Biol Psychiatry 2009, 33:917–920. This is a review of antipsychotic dosing principles in older adults and current theories regarding increased drug sensitivity in this population.CrossRefPubMed • Uchida H, Mamo DC: Dosing of antipsychotics in schizophrenia across the life-spectrum. Prog Neuropsychopharmacol Biol Psychiatry 2009, 33:917–920. This is a review of antipsychotic dosing principles in older adults and current theories regarding increased drug sensitivity in this population.CrossRefPubMed
12.
Zurück zum Zitat Kennedy JS, Jeste D, Kaiser CJ, et al.: Olanzapine vs haloperidol in geriatric schizophrenia: analysis of data from a double-blind controlled trial. Int J Geriatr Psychiatry 2003, 18:1013–1020.CrossRefPubMed Kennedy JS, Jeste D, Kaiser CJ, et al.: Olanzapine vs haloperidol in geriatric schizophrenia: analysis of data from a double-blind controlled trial. Int J Geriatr Psychiatry 2003, 18:1013–1020.CrossRefPubMed
13.
Zurück zum Zitat Jeste DV, Barak Y, Madhusoodanan S, et al.: International multisite double-blind trial of the atypical antipsychotics risperidone and olanzapine in 175 elderly patients with chronic schizophrenia. Am J Geriatr Psychiatry 2003, 11:638–647. (Published erratum appears in Am J Geriatr Psychiatry 2004, 12:49).PubMed Jeste DV, Barak Y, Madhusoodanan S, et al.: International multisite double-blind trial of the atypical antipsychotics risperidone and olanzapine in 175 elderly patients with chronic schizophrenia. Am J Geriatr Psychiatry 2003, 11:638–647. (Published erratum appears in Am J Geriatr Psychiatry 2004, 12:49).PubMed
14.
Zurück zum Zitat Riedel M, Eich FX, Moller HJ: A pilot study of the safety and efficacy of amisulpride and risperidone in elderly psychotic patients. Eur Psychiatry 2009, 24:149–153.CrossRefPubMed Riedel M, Eich FX, Moller HJ: A pilot study of the safety and efficacy of amisulpride and risperidone in elderly psychotic patients. Eur Psychiatry 2009, 24:149–153.CrossRefPubMed
15.
Zurück zum Zitat Lemmens P, Brecher M, Van Baelen B: A combined analysis of double-blind studies with risperidone vs. placebo and other antipsychotic agents: factors associated with extrapyramidal symptoms. Acta Psychiatr Scand 1999, 99:160–170.CrossRefPubMed Lemmens P, Brecher M, Van Baelen B: A combined analysis of double-blind studies with risperidone vs. placebo and other antipsychotic agents: factors associated with extrapyramidal symptoms. Acta Psychiatr Scand 1999, 99:160–170.CrossRefPubMed
16.
Zurück zum Zitat Jabs BE, Bartsch AJ, Pfuhlmann B: Susceptibility to neuroleptic-induced parkinsonism—age and increased substantia nigra echogenicity as putative risk factors. Eur Psychiatry 2003, 18:177–181.CrossRefPubMed Jabs BE, Bartsch AJ, Pfuhlmann B: Susceptibility to neuroleptic-induced parkinsonism—age and increased substantia nigra echogenicity as putative risk factors. Eur Psychiatry 2003, 18:177–181.CrossRefPubMed
17.
Zurück zum Zitat Jeste DV: Tardive dyskinesia rates with atypical antipsychotics in older adults. J Clin Psychiatry 2004, 65(Suppl 9):21–24.PubMed Jeste DV: Tardive dyskinesia rates with atypical antipsychotics in older adults. J Clin Psychiatry 2004, 65(Suppl 9):21–24.PubMed
18.
Zurück zum Zitat Jeste DV, Okamoto A, Napolitano J, et al.: Low incidence of persistent tardive dyskinesia in elderly patients with dementia treated with risperidone. Am J Psychiatry 2000, 157:1150–1155.CrossRefPubMed Jeste DV, Okamoto A, Napolitano J, et al.: Low incidence of persistent tardive dyskinesia in elderly patients with dementia treated with risperidone. Am J Psychiatry 2000, 157:1150–1155.CrossRefPubMed
19.
Zurück zum Zitat Correll CU, Leucht S, Kane JM: Lower risk for tardive dyskinesia associated with second-generation antipsychotics: a systematic review of 1-year studies. Am J Psychiatry 2004, 161:414–425.CrossRefPubMed Correll CU, Leucht S, Kane JM: Lower risk for tardive dyskinesia associated with second-generation antipsychotics: a systematic review of 1-year studies. Am J Psychiatry 2004, 161:414–425.CrossRefPubMed
20.
Zurück zum Zitat Sachdev P, Kruk J: Clinical characteristics and predisposing factors in acute drug-induced akathisia. Arch Gen Psychiatry 1994, 51:963–974.PubMed Sachdev P, Kruk J: Clinical characteristics and predisposing factors in acute drug-induced akathisia. Arch Gen Psychiatry 1994, 51:963–974.PubMed
21.
Zurück zum Zitat Modestin J, Wehrli MV, Stephan PL, Agarwalla P: Evolution of neuroleptic-induced extrapyramidal syndromes under long-term neuroleptic treatment. Schizophr Res 2008, 100:97–107.CrossRefPubMed Modestin J, Wehrli MV, Stephan PL, Agarwalla P: Evolution of neuroleptic-induced extrapyramidal syndromes under long-term neuroleptic treatment. Schizophr Res 2008, 100:97–107.CrossRefPubMed
22.
Zurück zum Zitat Addonizio G, Alexopoulos GS: Drug-induced dystonia in young and elderly patients. Am J Psychiatry 1988, 145:869–871.PubMed Addonizio G, Alexopoulos GS: Drug-induced dystonia in young and elderly patients. Am J Psychiatry 1988, 145:869–871.PubMed
23.
Zurück zum Zitat Hien le TT, Cumming RG, Cameron ID, et al.: Atypical antipsychotic medications and risk of falls in residents of aged care facilities. J Am Geriatr Soc 2005, 53:1290–1295.CrossRef Hien le TT, Cumming RG, Cameron ID, et al.: Atypical antipsychotic medications and risk of falls in residents of aged care facilities. J Am Geriatr Soc 2005, 53:1290–1295.CrossRef
24.
Zurück zum Zitat Schneeweiss S, Setoguchi S, Brookhart A, et al.: Risk of death associated with the use of conventional versus atypical antipsychotic drugs among elderly patients. CMAJ 2007, 176:627–632. (Published erratum appears in CMAJ 2007, 176:1613.)PubMed Schneeweiss S, Setoguchi S, Brookhart A, et al.: Risk of death associated with the use of conventional versus atypical antipsychotic drugs among elderly patients. CMAJ 2007, 176:627–632. (Published erratum appears in CMAJ 2007, 176:1613.)PubMed
25.
Zurück zum Zitat Gill SS, Bronskill SE, Normand SL, et al.: Antipsychotic drug use and mortality in older adults with dementia. Ann Intern Med 2007, 146:775–786.PubMed Gill SS, Bronskill SE, Normand SL, et al.: Antipsychotic drug use and mortality in older adults with dementia. Ann Intern Med 2007, 146:775–786.PubMed
26.
Zurück zum Zitat Setoguchi S, Wang PS, Alan Brookhart M, et al.: Potential causes of higher mortality in elderly users of conventional and atypical antipsychotic medications. J Am Geriatr Soc 2008, 56:1644–1650.CrossRefPubMed Setoguchi S, Wang PS, Alan Brookhart M, et al.: Potential causes of higher mortality in elderly users of conventional and atypical antipsychotic medications. J Am Geriatr Soc 2008, 56:1644–1650.CrossRefPubMed
27.
Zurück zum Zitat Knol W, van Marum RJ, Jansen PA, et al.: Antipsychotic drug use and risk of pneumonia in elderly people. J Am Geriatr Soc 2008, 56:661–666.CrossRefPubMed Knol W, van Marum RJ, Jansen PA, et al.: Antipsychotic drug use and risk of pneumonia in elderly people. J Am Geriatr Soc 2008, 56:661–666.CrossRefPubMed
28.
Zurück zum Zitat Harvey PD, Napolitano JA, Mao L, Gharabawi G: Comparative effects of risperidone and olanzapine on cognition in elderly patients with schizophrenia or schizoaffective disorder. Int J Geriatr Psychiatry 2003, 18:820–829.CrossRefPubMed Harvey PD, Napolitano JA, Mao L, Gharabawi G: Comparative effects of risperidone and olanzapine on cognition in elderly patients with schizophrenia or schizoaffective disorder. Int J Geriatr Psychiatry 2003, 18:820–829.CrossRefPubMed
29.
Zurück zum Zitat Cuesta MJ, Jalón EG, Campos MS, Peralta V: Cognitive effectiveness of olanzapine and risperidone in first-episode psychosis. Br J Psychiatry 2009, 194:439–445.CrossRefPubMed Cuesta MJ, Jalón EG, Campos MS, Peralta V: Cognitive effectiveness of olanzapine and risperidone in first-episode psychosis. Br J Psychiatry 2009, 194:439–445.CrossRefPubMed
30.
Zurück zum Zitat Davidson M, Galderisi S, Weiser M, et al.: Cognitive effects of antipsychotic drugs in first-episode schizophrenia and schizophreniform disorder: a randomized, open-label clinical trial (EUFEST). Am J Psychiatry 2009, 166:675–682. (Published erratum appears in Am J Psychiatry 2009, 166:731.)CrossRefPubMed Davidson M, Galderisi S, Weiser M, et al.: Cognitive effects of antipsychotic drugs in first-episode schizophrenia and schizophreniform disorder: a randomized, open-label clinical trial (EUFEST). Am J Psychiatry 2009, 166:675–682. (Published erratum appears in Am J Psychiatry 2009, 166:731.)CrossRefPubMed
31.
Zurück zum Zitat Hori H, Noguchi H, Hashimoto R, et al.: Antipsychotic medication and cognitive function in schizophrenia. Schizophr Res 2006, 86:138–146.CrossRefPubMed Hori H, Noguchi H, Hashimoto R, et al.: Antipsychotic medication and cognitive function in schizophrenia. Schizophr Res 2006, 86:138–146.CrossRefPubMed
32.
Zurück zum Zitat Morrens M, Wezenberg E, Verkes RJ, et al.: Psychomotor and memory effects of haloperidol, olanzapine, and paroxetine in healthy subjects after short-term administration. J Clin Psychopharmacol 2007, 27:15–21.CrossRefPubMed Morrens M, Wezenberg E, Verkes RJ, et al.: Psychomotor and memory effects of haloperidol, olanzapine, and paroxetine in healthy subjects after short-term administration. J Clin Psychopharmacol 2007, 27:15–21.CrossRefPubMed
33.
Zurück zum Zitat Uchida H, Rajji TK, Mulsant BH, et al.: D2 receptor blockade by risperidone correlates with attention deficits in late-life schizophrenia. J Clin Psychopharmacol 2009, 29:571–575.CrossRefPubMed Uchida H, Rajji TK, Mulsant BH, et al.: D2 receptor blockade by risperidone correlates with attention deficits in late-life schizophrenia. J Clin Psychopharmacol 2009, 29:571–575.CrossRefPubMed
34.
Zurück zum Zitat Rajji TK, Mulsant BH: Nature and course of cognitive function in late-life schizophrenia: a systematic review. Schizophr Res 2008, 102:122–140.CrossRefPubMed Rajji TK, Mulsant BH: Nature and course of cognitive function in late-life schizophrenia: a systematic review. Schizophr Res 2008, 102:122–140.CrossRefPubMed
35.
Zurück zum Zitat Haring C, Meise U, Humpel C, et al.: Dose-related plasma levels of clozapine: influence of smoking behaviour, sex and age. Psychopharmacology (Berl) 1989, 99(Suppl):S38–S40.CrossRef Haring C, Meise U, Humpel C, et al.: Dose-related plasma levels of clozapine: influence of smoking behaviour, sex and age. Psychopharmacology (Berl) 1989, 99(Suppl):S38–S40.CrossRef
36.
Zurück zum Zitat Jann MW, Grimsley SR, Gray EC, Chang WH: Pharmacokinetics and pharmacodynamics of clozapine. Clin Pharmacokinet 1993, 24:161–176.CrossRefPubMed Jann MW, Grimsley SR, Gray EC, Chang WH: Pharmacokinetics and pharmacodynamics of clozapine. Clin Pharmacokinet 1993, 24:161–176.CrossRefPubMed
37.
Zurück zum Zitat Bigos KL, Pollock BG, Coley KC, et al.: Sex, race, and smoking impact olanzapine exposure. J Clin Pharmacol 2008, 48:157–165.CrossRefPubMed Bigos KL, Pollock BG, Coley KC, et al.: Sex, race, and smoking impact olanzapine exposure. J Clin Pharmacol 2008, 48:157–165.CrossRefPubMed
38.
Zurück zum Zitat Ng W, Uchida H, Ismail Z, et al.: Clozapine exposure and the impact of smoking and gender: a population pharmacokinetic study. Ther Drug Monit 2009, 31:360–366.CrossRefPubMed Ng W, Uchida H, Ismail Z, et al.: Clozapine exposure and the impact of smoking and gender: a population pharmacokinetic study. Ther Drug Monit 2009, 31:360–366.CrossRefPubMed
39.
Zurück zum Zitat Lane HY, Chang YC, Chang WH, et al.: Effects of gender and age on plasma levels of clozapine and its metabolites: analyzed by critical statistics. J Clin Psychiatry 1999, 60:36–40.PubMed Lane HY, Chang YC, Chang WH, et al.: Effects of gender and age on plasma levels of clozapine and its metabolites: analyzed by critical statistics. J Clin Psychiatry 1999, 60:36–40.PubMed
40.
Zurück zum Zitat Snoeck E, Van Peer A, Sack M, et al.: Influence of age, renal and liver impairment on the pharmacokinetics of risperidone in man. Psychopharmacology (Berl) 1995, 122:223–229.CrossRef Snoeck E, Van Peer A, Sack M, et al.: Influence of age, renal and liver impairment on the pharmacokinetics of risperidone in man. Psychopharmacology (Berl) 1995, 122:223–229.CrossRef
41.
Zurück zum Zitat Callaghan JT, Bergstrom RF, Ptak LR, Beasley CM: Olanzapine. Pharmacokinetic and pharmacodynamic profile: Clin Pharmacokinet 1999, 37:177–193.PubMed Callaghan JT, Bergstrom RF, Ptak LR, Beasley CM: Olanzapine. Pharmacokinetic and pharmacodynamic profile: Clin Pharmacokinet 1999, 37:177–193.PubMed
42.
Zurück zum Zitat Wilner KD, Tensfeldt TG, Baris B, et al.: Single- and multiple-dose pharmacokinetics of ziprasidone in healthy young and elderly volunteers. Br J Clin Pharmacol 2000, 49(Suppl 1):15S–20S.CrossRefPubMed Wilner KD, Tensfeldt TG, Baris B, et al.: Single- and multiple-dose pharmacokinetics of ziprasidone in healthy young and elderly volunteers. Br J Clin Pharmacol 2000, 49(Suppl 1):15S–20S.CrossRefPubMed
43.
Zurück zum Zitat Brenner SS, Klotz U: P-glycoprotein function in the elderly. Eur J Clin Pharmacol 2004, 60:97–102.CrossRefPubMed Brenner SS, Klotz U: P-glycoprotein function in the elderly. Eur J Clin Pharmacol 2004, 60:97–102.CrossRefPubMed
44.
Zurück zum Zitat Volkow ND, Wang GJ, Fowler JS, et al.: Imaging endogenous dopamine competition with [11C]raclopride in the human brain. Synapse 1994, 16:255–262.CrossRefPubMed Volkow ND, Wang GJ, Fowler JS, et al.: Imaging endogenous dopamine competition with [11C]raclopride in the human brain. Synapse 1994, 16:255–262.CrossRefPubMed
45.
Zurück zum Zitat Eidelberg D, Takikawa S, Dhawan V, et al.: Striatal 18F-dopa uptake: absence of an aging effect. J Cereb Blood Flow Metab 1993, 13:881–888.PubMed Eidelberg D, Takikawa S, Dhawan V, et al.: Striatal 18F-dopa uptake: absence of an aging effect. J Cereb Blood Flow Metab 1993, 13:881–888.PubMed
46.
Zurück zum Zitat Ota M, Yasuno F, Ito H, et al.: Age-related decline of dopamine synthesis in the living human brain measured by positron emission tomography with L-[beta-11C]DOPA. Life Sci 2006, 79:730–736.CrossRefPubMed Ota M, Yasuno F, Ito H, et al.: Age-related decline of dopamine synthesis in the living human brain measured by positron emission tomography with L-[beta-11C]DOPA. Life Sci 2006, 79:730–736.CrossRefPubMed
47.
Zurück zum Zitat Volkow ND, Fowler JS, Wang GJ, et al.: Decreased dopamine transporters with age in health human subjects. Ann Neurol 1994, 36:237–239.CrossRefPubMed Volkow ND, Fowler JS, Wang GJ, et al.: Decreased dopamine transporters with age in health human subjects. Ann Neurol 1994, 36:237–239.CrossRefPubMed
48.
Zurück zum Zitat Jaber M, Jones S, Giros B, Caron MG: The dopamine transporter: a crucial component regulating dopamine transmission. Mov Disord 1997, 12:629–633.CrossRefPubMed Jaber M, Jones S, Giros B, Caron MG: The dopamine transporter: a crucial component regulating dopamine transmission. Mov Disord 1997, 12:629–633.CrossRefPubMed
49.
Zurück zum Zitat Fowler JS, Volkow ND, Wang GJ, et al.: Age-related increases in brain monoamine oxidase B in living healthy human subjects. Neurobiol Aging 1997, 18:431–435.CrossRefPubMed Fowler JS, Volkow ND, Wang GJ, et al.: Age-related increases in brain monoamine oxidase B in living healthy human subjects. Neurobiol Aging 1997, 18:431–435.CrossRefPubMed
50.
Zurück zum Zitat Cabello CR, Thune JJ, Pakkenberg H, Pakkenberg B: Ageing of substantia nigra in humans: cell loss may be compensated by hypertrophy. Neuropathol Appl Neurobiol 2002, 28:283–291.CrossRefPubMed Cabello CR, Thune JJ, Pakkenberg H, Pakkenberg B: Ageing of substantia nigra in humans: cell loss may be compensated by hypertrophy. Neuropathol Appl Neurobiol 2002, 28:283–291.CrossRefPubMed
51.
Zurück zum Zitat Rinne JO: Muscarinic and dopaminergic receptors in the aging human brain. Brain Res 1987, 404:162–168.CrossRefPubMed Rinne JO: Muscarinic and dopaminergic receptors in the aging human brain. Brain Res 1987, 404:162–168.CrossRefPubMed
52.
Zurück zum Zitat Hegner D, Platt D, Heckers H, et al.: Age-dependent physiochemical and biochemical studies of human red cell membranes. Mech Ageing Dev 1979, 10:117–130.CrossRefPubMed Hegner D, Platt D, Heckers H, et al.: Age-dependent physiochemical and biochemical studies of human red cell membranes. Mech Ageing Dev 1979, 10:117–130.CrossRefPubMed
53.
Zurück zum Zitat Uchida H, Kapur S, Mulsant BH, et al.: Sensitivity of older patients to antipsychotic motor side effects: a PET study examining potential mechanisms. Am J Geriatr Psychiatry 2009, 17:255–263.CrossRefPubMed Uchida H, Kapur S, Mulsant BH, et al.: Sensitivity of older patients to antipsychotic motor side effects: a PET study examining potential mechanisms. Am J Geriatr Psychiatry 2009, 17:255–263.CrossRefPubMed
54.
Zurück zum Zitat Wong DF, Pearlson GD, Tune LE, et al.: Quantification of neuroreceptors in the living human brain: IV. Effect of aging and elevations of D2-like receptors in schizophrenia and bipolar illness. J Cereb Blood Flow Metab 1997, 17:331–342.CrossRefPubMed Wong DF, Pearlson GD, Tune LE, et al.: Quantification of neuroreceptors in the living human brain: IV. Effect of aging and elevations of D2-like receptors in schizophrenia and bipolar illness. J Cereb Blood Flow Metab 1997, 17:331–342.CrossRefPubMed
55.
Zurück zum Zitat Seeman P, Bzowej NH, Guan HC, et al.: Human brain dopamine receptors in children and aging adults. Synapse 1987, 1:399–404.CrossRefPubMed Seeman P, Bzowej NH, Guan HC, et al.: Human brain dopamine receptors in children and aging adults. Synapse 1987, 1:399–404.CrossRefPubMed
56.
Zurück zum Zitat Jeste DV, Lacro JP, Gilbert PL, et al.: Treatment of late-life schizophrenia with neuroleptics. Schizophr Bull 1993, 19:817–830.PubMed Jeste DV, Lacro JP, Gilbert PL, et al.: Treatment of late-life schizophrenia with neuroleptics. Schizophr Bull 1993, 19:817–830.PubMed
57.
Zurück zum Zitat Mamo DC, Sweet RA, Chengappa KN, et al.: The effect of age on the pharmacological management of ambulatory patients treated with depot neuroleptic medications for schizophrenia and related psychotic disorders. Int J Geriatr Psychiatry 2002, 17:1012–1017.CrossRefPubMed Mamo DC, Sweet RA, Chengappa KN, et al.: The effect of age on the pharmacological management of ambulatory patients treated with depot neuroleptic medications for schizophrenia and related psychotic disorders. Int J Geriatr Psychiatry 2002, 17:1012–1017.CrossRefPubMed
58.
Zurück zum Zitat Uchida H, Suzuki T, Mamo DC, et al.: Effects of age and age of onset on prescribed antipsychotic dose in schizophrenia spectrum disorders: a survey of 1,418 patients in Japan. Am J Geriatr Psychiatry 2008, 16:584–593.CrossRefPubMed Uchida H, Suzuki T, Mamo DC, et al.: Effects of age and age of onset on prescribed antipsychotic dose in schizophrenia spectrum disorders: a survey of 1,418 patients in Japan. Am J Geriatr Psychiatry 2008, 16:584–593.CrossRefPubMed
59.
Zurück zum Zitat Uchida H, Graff-Guerrero A, Mulsant BH, et al.: Long-term stability of measuring D(2) receptors in schizophrenia patients treated with antipsychotics. Schizophr Res 2009, 109:130–133.CrossRefPubMed Uchida H, Graff-Guerrero A, Mulsant BH, et al.: Long-term stability of measuring D(2) receptors in schizophrenia patients treated with antipsychotics. Schizophr Res 2009, 109:130–133.CrossRefPubMed
60.
Zurück zum Zitat Meyer JH, Wilson AA, Sagrati S, et al.: Serotonin transporter occupancy of five selective serotonin reuptake inhibitors at different doses: an [11C]DASB positron emission tomography study. Am J Psychiatry 2004, 161:826–835.CrossRefPubMed Meyer JH, Wilson AA, Sagrati S, et al.: Serotonin transporter occupancy of five selective serotonin reuptake inhibitors at different doses: an [11C]DASB positron emission tomography study. Am J Psychiatry 2004, 161:826–835.CrossRefPubMed
Metadaten
Titel
Sensitivity to Antipsychotic Drugs in Older Adults
verfasst von
Chloe Leon
Philip Gerretsen
Hiroyuki Uchida
Takefumi Suzuki
Tarek Rajji
David C. Mamo
Publikationsdatum
01.02.2010
Verlag
Current Science Inc.
Erschienen in
Current Psychiatry Reports / Ausgabe 1/2010
Print ISSN: 1523-3812
Elektronische ISSN: 1535-1645
DOI
https://doi.org/10.1007/s11920-009-0080-3

Weitere Artikel der Ausgabe 1/2010

Current Psychiatry Reports 1/2010 Zur Ausgabe

Update Psychiatrie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.